AZD5305 + paclitaxel

**AZD5305 + paclitaxel** is an investigational combination therapy for advanced solid tumors, particularly ovarian, breast, prostate, and pancreatic cancers. AZD5305 (saruparib) is a highly selective next-generation inhibitor of PARP1 (poly-ADP ribose polymerase 1), which traps and inhibits this DNA repair enzyme, causing increased cancer cell death, especially in tumors with defective homologous recombination repair (e.g., BRCA1/2, PALB2, RAD51C/D mutations)[4][5][9]. Paclitaxel is a well-established intravenous anti-microtubule chemotherapeutic that inhibits cell division and promotes apoptosis. The combination is designed to exploit the synergy between DNA damage induced by paclitaxel and the impaired DNA repair caused by AZD5305, potentially improving efficacy over monotherapy or previous PARP inhibitors[5][7][9]. The therapy is currently being investigated in modular phase 1/2 clinical trials assessing safety, tolerability, and preliminary efficacy in patients with advanced solid malignancies[1][3][5][7][9]. AZD5305 has shown promising preclinical and early clinical results for tolerability and anti-cancer activity.